p27 Loss Is Associated with Poor Prognosis in Gastroenteropancreatic Neuroendocrine Tumors

Hee Sung Kim; Hye Seung Lee; Kyung Han Nam; Jiwoon Choi; Woo Ho Kim

doi:10.4143/crt.2013.102

Articles

Page Path: HOME > Cancer Res Treat > Volume 46(4); 2014 > Article

Original Article p27 Loss Is Associated with Poor Prognosis in Gastroenteropancreatic Neuroendocrine Tumors: Hee Sung Kim, MD, PhD¹, Hye Seung Lee, MD, PhD², Kyung Han Nam, MD³, Jiwoon Choi, MD³, Woo Ho Kim, MD, PhD^3,; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2014;46(4):383-392.
DOI: https://doi.org/10.4143/crt.2013.102
Published online: July 17, 2014

¹Department of Pathology, Chung-Ang University College of Medicine, Seoul, Korea

²Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

³Department of Pathology, Seoul National University College of Medicine, Seoul, Korea

Correspondence: Woo Ho Kim, MD, PhD Department of Pathology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 110-799, Korea
Tel: 82-2-740-8269 Fax: 82-2-765-5600 E-mail: woohokim@snu.ac.kr

• Received: July 4, 2013 • Accepted: November 1, 2013

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

12,550 Views
66 Download
26 Web of Science
22 Crossref
27 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent a heterogeneous disease group originating from the neuroendocrine cells. Identification of prognostic markers, related to neuroendocrine tissue-selective tumorigenesis, is necessary to find therapeutic targets.
Materials and Methods
A total of 327 patients with GEP-NETs were included in this study; there were 49 gastric, 29 duodenal, 49 pancreatic, 12 hepatobiliary, 33 appendiceal, 5 proximal colon, and 150 distal colon cases. We performed immunostaining with the tissue microarray method for menin, p27, and p18.
Results
We observed negative staining for menin, p27, and p18 in 34%, 21%, and 56% of GEP-NETs, respectively. The loss of p27, but not menin, was positively correlated with the grade of Ki-67. Menin–/p27–, menin–/p27+, menin+/p27–, and menin+/p27+ phenotype groups included 13%, 22%, 8%, and 57% of patients, respectively. A dichotomized comparison showed that menin– or p27– tumors were significantly associated with foregut and midgut localizations, high World Health Organization (WHO) grade, lymph node metastasis, and more advanced stage as compared to menin+/p27+ patients. Kaplan-Meier analysis for the overall survival showed that p27 loss was significantly associated with decreased survival. Multivariate analysis showed that p27 loss is an independent factor for poor overall survival.
Conclusion
Our results revealed that the loss of p27 is associated with poor prognosis and the menin-p27 pathway is important in the tumorigenesis of GEP-NETs.
Key words: Cyclin-dependent kinase inhibitor p27, Menin, Neuroendocrine tumors, Gastrointestinal neoplasms, Pancreatic neoplasms, Prognosis, Biological tumor markers

Introduction

Gastroenteropancreatic neuroendocrine tumors (GEPNETs) comprise 65-75% of all NETs and arise from the enterochromaffin cells distributed throughout the digestive system. The prevalence of GEP-NETs has been estimated to be 2.23/100,000, with an annual onset incidence of 1.01/100,000 [1]. The incidence and prevalence of this kind of tumor have increased over the recent decades, according to a recent analysis of the Surveillance, Epidemiology, and End Results (SEER) Program database in the United States [2]. Although most NETs present indolent progression, a significant number of patients were diagnosed presenting with unresectable or metastatic disease.

The MEN1 gene is located on chromosome 11q13 and consists of 10 exons that encode a protein of 610 amino acids, referred to as menin [3]. Mutation in the MEN1 gene has been identified in approximately 90% of familial cases and 27% of sporadic cases of MEN1 syndrome. More than 500 different somatic and germline MEN1 gene mutations have been identified; however, no obvious genotype-phenotype correlation is discernible with these mutations [4]. Based on both reverse transcription polymerase chain reaction and immunoblotting, menin expression was reported to be down-regulated in MEN1 tumors [5]. Menin has functions in DNA stability and gene regulation, and it can act as a tumor suppressor [6]. It has been shown to function as a tumor suppressor through transcriptional activation of the cyclin-dependent kinase (CDK) inhibitors, p18 and p27 [7]. Loss of menin was conversely associated with the reduction of both p18 and p27 gene expression [8]. Menin has been shown to bind to the promoters of p18 and p27 together with mixed lineage leukemia protein (MLL) histone methyltransferase in mouse pancreatic islets [7,8].

p27 is encoded by cyclin-dependent kinase inhibitor 1B (CDKN1B), and inhibitory binding of p27 to CDK2/cyclin E and CDK2/cyclin A complexes in the nucleus arrests cells at G1/S in the cell cycle [9]. Low expression of p27 has been observed in about 50% of all human cancers and this condition is usually correlated with histological aggressiveness and poor outcome in patients with breast, colorectal, ovary, prostate, bladder, and pancreatic tumors [10-12]. Loss of p27 expression was also found in endocrine neoplasms, such as human pituitary and parathyroid hyperplasias, adenomas, sporadic pheochromocytoma, as well as GEPNETs [12-15].

A mutation in the p27 gene was recently identified in a family with what appeared to be MEN1-related tumors, which have now been proposed to be called MEN type 4 (MEN4) [9]. p27-null mice develop intermediate lobe pituitary adenomas as the sole tumor phenotype, suggesting that pituitary cells were particularly sensitive to the defects in cell cycle regulation [9]. That finding suggested that p27 is associated with tumorigenesis of the neuroendocrine cells. Since the growth of mouse endocrine organs is sensitive to simultaneous loss of p27 and p18 activities [16,17], it was suggested that p27 and p18 may have partially overlapping functions in the maintenance of growth control for diverse neuroendocrine cells.

Up until now, only a few studies have focused on the loss of menin, p27, and p18 in GEP-NETs [13,14,18], and the clinical significance of the loss of these proteins has been controversial. We hypothesized that there is a tissue-specific tumorigenesis pathway that involves menin protein alteration with subsequent p27 loss in GEP-NETs. Herein, we examine the GEP-NET expression of menin, p27, and p18 [19].

Materials and Methods

1. Patients

The medical records of 327 patients (mean age, 53 years; range, 11 to 91 years) with histopathologically proven neuroendocrine tumors of the gastroenteropancreatic tract, who were treated at Seoul National University Hospital (n=230) or Seoul National University Bundang Hospital (n=97) between 1989 and 2009, were analyzed retrospectively.

Histopathologic confirmation of the diagnosis of GEP-NET was required to be included in this study. The patient files were reviewed systematically for the date of initial diagnosis, localization of the primary tumor, histopathologic diagnosis, tissue site from which samples were taken for histopatho-logic diagnosis, clinical staging at initial diagnosis, and the presence of a functional syndrome (Table 1). There were 145 female and 182 male patients. A family history of the disease was present in seven patients. Twenty-six patients had symptoms at presentation. Five patients had endocrine disorders. Standard histopathological examinations included assessment of the pathological tumor stage according to the criteria described in the 7th edition of the American Joint Committee on Cancer (AJCC) Staging Manual [20]. Histologic classifications were performed as recommended by the World Health Organization (WHO) 2010 classification [21].

The formalin-fixed and paraffin-embedded tumor tissues of patients treated from 1989 to 2008 were retrieved from the archives at the Departments of Pathology of Seoul National University Hospitals in Seoul and Bundang, Korea. The inclusion criteria were primary GEP-NET with or without metastases diagnosed by endoscopic biopsy and surgical resection.

Among the 327 patients, follow-up and survival information was obtained for 262 patients. The mean follow-up period was 53 months (range, 1 to 243 months), as of February 2012. The study protocol was approved by the Institutional Review Board committee of Seoul National University Hospital (C-1012-027-343). Patient survival data, including dates and causes of death, were obtained from the Korean Central Cancer Registry at the Ministry of Health and Welfare.

Fifty-two patients received adjuvant treatments, including postoperative chemotherapy (n=25), postoperative chemotherapy/radio frequency ablation (RFA)/sandostatin longacting release (LAR) (n=1), preoperative chemotherapy (n=2), preoperative and postoperative chemotherapy (n=1), postoperative radiotherapy (RT) and chemotherapy (n=7), RT (n=2), RFA (n=4), transarterial chemoembolization (TACE) (n=4), transarterial embolization (TAE) and RT (n=1), TACE and chemotherapy (n=1), TACE and RAD001 trial (n=1), TACE+RFA+RAD001 trial (n=1), TAE+ interferon+streptomycin+adriamycin, sandostatin+LAR+ thalidomide+Avastin+RAD001 (n=1), and TACE+RFA+RT+ sandostatin+chemotherapy (n=1).

2. Tissue array preparation

Tissues obtained from patients were routinely fixed in 10% buffered formalin and embedded in paraffin blocks. After screening the available slides for each case, we selected a paraffin block that was well fixed and contained a representative section of the tumor. One tissue column (2.0 mm in diameter) was obtained from each selected paraffin block and arranged in new, separate paraffin blocks with 60 holes, using a trephine apparatus (Superbiochips Laboratories, Seoul, Korea). Microarray blocks were then sectioned at 4 μm and processed for immunohistochemical staining. After removing the paraffin with xylene, the sections were rehydrated with graded ethanol and immersed in Tris-buffered saline.

3. Immunohistochemistry

Anti-menin rabbit monoclonal (1:200, Epitomics, Burlingame, CA), p18 mouse monoclonal (1:50, Thermo Scientific, San Jose, CA), and p27 rabbit polyclonal (1:300, Spring Bioscience, Pleasanton, CA) antibodies were used for immunohistochemistry. Staining was done by a labeled avidin-biotin-peroxidase complex, using the ABC kit from Vector Labs (Vectastain Elite ABC kit, Vector Labs, Burlingame, CA) after antigen retrieval. For color development, diaminobenzidine was used. The nuclear Ki-67 labeling index was expressed as the percentage of positively stained cells with respect to 100 cells in 10 high-power fields. For p27 immunostaining, the nuclear staining and cytoplasmic staining were evaluated separately. Cases with no staining of either cytoplasm or nucleus were considered to be negative. p18 was regarded as positive when nuclear staining was present in more than 10% of the cells. Menin staining was regarded as positive when more than 10% of the cells had positive staining, in either the nuclei or cytoplasm.

4. Statistical analyses

Our series contains statistical limitations because of heterogeneity among the primary sites and treatment modalities, as well as the 20-year collection period. Survival rates were calculated using the Kaplan-Meier method, and groups were compared using the log rank test. Kaplan-Meier curves were plotted using the overall survival (OS) data. Multivariate Cox regression analysis with variables including Ki-67 grade, presence of lymph node metastasis, p27-positivity, and menin-positivity was performed. All p < 0.05 were considered statistically significant. Statistical analysis was performed using the SPSS ver. 15.0 (SPSS Inc., Chicago, IL).

Results

1. Expression of menin, p27, and p18 in GEP-NETs

Staining of menin, p27, and p18 was evident in the nuclei of the normal pancreatic acini, ducts, and islet cells. Menin loss was observed in 34% (100/294) of the GEP-NET cells. Frequencies of p27-negativity and -positivity were 21% (61/290) and 79% (229/290; 70% nuclear positivity and 9% cytoplasmic positivity), respectively. p18-negativity was observed in 56% of cells (169/300) (Fig. 1).

2. Clinicopathologic correlations with menin and p27 expression

Menin-negativity was more frequent in the foregut and pancreas, and in AJCC stages higher than II. p27-negativity was more frequent in the foregut or midgut locations, in higher grades by WHO classification, and in higher AJCC stages (Table 2).

To see the relationship between menin and p27 expression levels, patients were categorized into four groups in accordance to a combination of menin and p27 expression. Menin–/p27–, menin–/p27+, menin+/p27–, and menin+/p27+ phenotype groups, which included 13% (37/290), 22% (63/290), 8% (24/290), and 57% (166/290) of patients, respectively. Among 61 p27– cases, 37 (61%) were menin–, while among 229 p27+ cases, 63 (28%) were menin–.

We performed comparative analyses among the 4 groups of menin+/p27+, menin–/p27–, menin–/p27+, and menin+/p27–. The tumors of the foregut or midgut had a greater loss of either menin or p27; whereas the menin+/p27+ phenotype were more frequent in hindgut tumors (p=0.001). In the classification of the GEP-NET cases into gastrointestinal and pancreatic NETs, pancreatic NETs were less frequently menin+/p27+ than were gastrointestinal NETs (44% vs. 60%, respectively), although this difference was not statistically significant. Tumors defined as low grade by the WHO classification (NET G1 and G2) (p=0.021), those that were AJCC stage I (p=0.002), and those without lymph node metastasis (p=0.002) were more frequently found in the menin+/p27+ phenotype group than in the other groups (Table 3).

The correlation of p27 expression with the expression levels of other relevant proteins was analyzed. The tumor proliferative index assessed using Ki-67 immunohistochemistry has been considered as a standard marker for therapeutic decisions in NETs. p27 loss was correlated with high grade Ki-67, but menin loss did not. Neither p27 expression nor menin expression was significantly associated with p18 expression (Table 4).

3. Survival analysis

The Kaplan-Meier analysis for the OS showed that menin+ patients had better rates of survival than menin– patients, but with borderline significance (p=0.055); p27+ patients had a significantly better rate of survival than p27– patients (p < 0.001). In subgroup analyses with the combination phenotypes in accordance to p27 and menin expression, menin+/p27+ showed the best OS, both among the 4 groups and 2 dichotomized groups (p < 0.001) (Fig. 2). In a multivariate analysis, including the variables of Ki-67 grade, lymph node status, p27 expression, and menin expression, high grade Ki-67, lymph node metastasis, and p27-negativity were associated with significantly worse OS (Table 5).

Discussion

Our study showed a loss of menin, p27, and p18 in 34%, 21%, and 56%, respectively, of GEP-NETs, and also found that the expression levels of those proteins are associated with the prognosis. In an analysis of the MEN1 gene and protein status in sporadic pancreatic endocrine neoplasms [22], somatic mutation of the MEN1 gene was detected in 15% of pancreatic NETs (25 of 169), whereas abnormal expression of menin was found in 80% of sporadic pancreatic NETs. Menin was also abnormally expressed in a significant number of NET cases lacking MEN1 mutations. These findings suggest that epigenetic regulation of the MEN1 gene plays a role in the tumorigenesis of neuroendocrine tumors [8].

Menin was found to be a part of a distinct MLL complex that contains histone methyl transferase (HMT) activity. This MLL-HMT complex specifically promotes the trimethylation of lysine 4 on histone H3 (H3K4) and, in such way, activates the transcription of homeobox domain (HOX) genes, p18 and p27 [8]. p18 and p27 are known to inhibit functions of the cell cycle regulators, like CDK2 and CDK4 [19]. The loss of function of menin leads to the down-regulation of p18 and p27, causing a deregulation of cell growth [7].

We observed a correlation of p27 loss with high Ki-67 grade and shorter overall survival, a finding that is consistent with previous results. p27 was investigated in endocrine tumors and a marked decrease was reported in the protein expression of hyperplastic tissues, as well as benign and malignant neoplasms compared with normal tissues [12]. Grabowski et al. [14] reported a loss of nuclear p27 expression and its prognostic role in relation to cyclin E and p53 mutations in GEP-NETs. In pheochromocytoma, p27 expression was reduced or lost in 56% of tumors [13].

A limitation of our study is that our cases were retrospectively collected and were composed of a heterogeneous patient group with seven primary sites, various pathologic stages, and different treatment modalities. In addition, as the cases were collected through 20 years of pathologic archives, survival analyses may be somewhat skewed and could be influenced by compounding effects.

A strength of our study is that we analyzed 327 patients with GEP-NETs, making our study the largest among all those ever published on tissue-based GEP-NET studies [14,18]. In addition, we are the first to analyze the interactions among menin, p27, and p18 proteins in a large clinical cohort of GEP-NETs. Our study showed that menin loss was also present in a substantial portion of the p27 loss cases, although the underlying molecular defects related to menin protein loss were not elucidated in this study. Further investigation of p27 dysregulation with regard to the steps of NET progression is needed.

Conclusion

There is a subset of GEP-NETs that loses menin and p27 simultaneously, and this finding suggests the presence of a pathway involving menin and p27 loss. p27 is an independent adverse prognostic factor in GEP-NETs.

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT ＆ Future Planning (NRF-2012R1A1A2004648).

Fig. 1.

Immunohistochemical expression of menin, p27, and p18 in gastroenteropancreatic neuroendocrine tumors. (A, D, G) menin. (B, E, H) p27. (C, F, I) p18. Upper, gastric neuroendocrine carcinoma with 90% of Ki-67; middle, gastric neuroendocrine tumor with 1% of Ki-67, lower, rectal neuroendocrine tumor with 3% of Ki-67.

Fig. 2.

Kaplan-Meier analysis of overall survival in gastroenteropancreatic neuroendocrine tumors. Survival curves according to p27 expression (A), menin expression (B), 4 phenotype groups by combination of menin and p27 expression (C), and dichotomized groups of menin+/p27+ and menin– or p27– (D).

Table 1.

Profile of patients with gastroenteropancreatic neuroendocrine tumors

Characteristic	No. (%) (n=327)
Gender
Female	145 (44)
Male	182 (56)
Clinical history
None	289 (88)
Family history	7 (2)
Symptomatic	26 (8)
Endocrine disorders	5 (2)
Primary site
Stomach	49 (15)
Duodenum	29 (9)
Pancreas	49 (15)
Hepatobiliary	12 (4)
Appendix	33 (10)
Proximal colon	5 (2)
Distal colon	150 (46)
Part
Foregut	139 (43)
Midgut	38 (12)
Hindgut	150 (46)
AJCC stage
I	251 (77)
II	27 (8)
III	23 (7)
IV	25 (8)
Unknown	1 (1)
Comorbidity
None	253 (77)
Malignancy	55 (17)
Benign neoplasm	19 (6)
Adjuvant treatment
No	276 (84)
Yes	51 (16)
Recurrence
Absent	282 (86)
Present	45 (14)
Status
Alive	220 (67)
Deceased	42 (13)
Unknown	65 (20)

AJCC, American Joint Committee on Cancer.

Table 2.

Clinicopathologic correlations of p27 and menin expressions in gastroenteropancreatic neuroendocrine tumors

Characteristic	Menin		p-value	p27		p-value
Characteristic	Negative	Positive	p-value	Negative	Positive	p-value
Total	100 (34)	194 (66)		61 (21)	229 (79)
Mean age (yr)	55	53		54	53
Gender			0.335			0.742
Female	41 (31)	91 (69)		26 (20)	103 (80)
Male	59 (36)	103 (64)		35 (22)	126 (78)
Part			0.023			<0.001
Foregut	52 (42)	72 (58)		37 (30)	86 (70)
Midgut	13 (37)	22 (63)		11 (33)	22 (67)
Hindgut	35 (26)	100(74)		13 (10)	121 (90)
Location			0.011			0.726
Gastrointestinal tract	76 (31)	170 (69)		50 (21)	192 (79)
Pancreas	24 (50)	24 (50)		11 (23)	37 (77)
WHO 2010 classification			0.629			0.001
NET G1	50 (31)	110 (69)		28 (18)	129 (82)
NET G2	26 (35)	48 (65)		9 (12)	64 (88)
NEC	14 (42)	19 (58)		13 (39)	20 (61)
MANEC	10 (37)	17 (63)		11 (41)	16 (59)
AJCC stage			0.002			0.002
I	63 (28)	160 (72)		37 (17)	182 (83)
II	15 (60)	10 (40)		12 (48)	13 (52)
III	8 (38)	13 (62)		4 (19)	17 (81)
IV	13 (54)	11 (46)		7 (29)	17(71)
Lymph node metastasis			0.065			0.499
Absent	74 (31)	163 (69)		47 (20)	186 (80)
Present	22 (45)	27 (55)		12 (24)	37 (76)

Values are presented as number (%). WHO, World Health Organization; NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma; MANEC, mixed adenoneuroendocrine carcinoma; AJCC, American Joint Committee on Cancer.

Table 3.

Clinicopathologic correlations of combined menin and p27 protein expressions in gastroenteropancreatic neuroendocrine tumors

Characteristic	Menin+/p27+	Menin-/p27-	Menin-/p27+	Menin+/p27-	p-value
Total	166 (57)	37 (13)	63 (22)	24 (8)
Mean age (yr)	53	54	55	54
Gender					0.251
Female	74 (57)	12 (9)	29 (22)	14 (11)
Male	92 (57)	25 (16)	34 (21)	10 (6)
Part					0.001
Foregut	57 (46)	23 (19)	29 (24)	14 (11)
Midgut	15 (45)	6 (18)	7 (21)	5 (15)
Hindgut	94 (70)	8 (6)	27 (20)	5 (4)
Gastrointestinal tract vs. pancreas					0.095
Gastrointestinal tract	145 (60)	29 (12)	47 (19)	21 (9)
Pancreas	21 (44)	8 (17)	16 (33)	3 (6)
WHO 2010 classification					0.021
NET G1	96 (61)	17 (11)	33 (21)	11 (7)
NET G2	44 (60)	6 (8)	20 (27)	3 (4)
NEC	13 (39)	7 (21)	7 (21)	6 (18)
MANEC	13 (48)	7 (26)	3 (11)	4 (15)
AJCC stage					0.002
I	141 (64)	22 (10)	41 (19)	15 (7)
II	6 (24)	8 (32)	7 (28)	4 (16)
III	11 (52)	2 (10)	6 (29)	2 (10)
IV	8 (33)	4 (17)	9 (38)	3 (13)
Lymph node metastasis					0.002
Absent	143 (61)	31 (13)	43 (18)	16 (7)
Present	19 (39)	4 (8)	18 (37)	8 (16)

Table 4.

Correlation of menin and p27 expression with expression of other proteins in gastroenteropancreatic neuroendocrine tumors

	p27		p-value	Menin		p-value
	Negative	Positive	p-value	Negative	Positive	p-value
Ki-67 grade			0.006			0.055
G1	40 (21)	149 (79)		74 (39)	117 (61)
G2	9 (13)	58 (87)		18 (26)	50 (74)
G3	11 (44)	14 (56)		5 (20)	20 (80)
p18			0.202			0.185
Negative	38 (23)	124 (77)		61 (38)	101 (62)
Positive	22 (17)	105 (83)		39 (30)	90 (70)

Values are presented as number (%).

Table 5.

Multivariate analysis for overall survival

Variable	No.	p-value	Hazard ratio	95% CI
Ki-67 grade		0.015		1.2-6.2
G2 or G3	71		2.7
G1	144
Lymph node metastasis		< 0.001		3.2-15.8
Present	38		7.2
Absent	177
p27		< 0.001		3.3-14.0
Negative	37		6.8
Positive	178
Menin		0.091		0.9-4.4
Negative	107		2.0
Positive	108

CI, confidence interval.

REFERENCES

1. Gastrointestinal Pathology Study Group of Korean Society of Pathologists; Cho MY, Sohn JH, Jin SY, Kim H, Jung ES, et al. Proposal for a standardized pathology report of gastroenteropancreatic neuroendocrine tumors: prognostic significance of pathological parameters. Korean J Pathol. 2013;47:227–37. Article PubMed PMC
2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72. Article PubMed
3. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276:404–7. Article PubMed
4. Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat. 2008;29:22–32. Article PubMed
5. Bhuiyan MM, Sato M, Murao K, Imachi H, Namihira H, Takahara J. Expression of menin in parathyroid tumors. J Clin Endocrinol Metab. 2000;85:2615–9. Article PubMed
6. Yang Y, Hua X. In search of tumor suppressing functions of menin. Mol Cell Endocrinol. 2007;265-266:34–41. Article PubMed PMC
7. Milne TA, Hughes CM, Lloyd R, Yang Z, Rozenblatt-Rosen O, Dou Y, et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A. 2005;102:749–54. Article PubMed PMC
8. Karnik SK, Hughes CM, Gu X, Rozenblatt-Rosen O, McLean GW, Xiong Y, et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci U S A. 2005;102:14659–64. Article PubMed PMC
9. Marinoni I, Pellegata NS. p27kip1: a new multiple endocrine neoplasia gene? Neuroendocrinology. 2011;93:19–28. Article PubMed
10. Duncan TJ, Al-Attar A, Rolland P, Harper S, Spendlove I, Durrant LG. Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer. Int J Gynecol Pathol. 2010;29:8–18. Article PubMed
11. Psyrri A, Bamias A, Yu Z, Weinberger PM, Kassar M, Markakis S, et al. Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. Clin Cancer Res. 2005;11:8384–90. Article PubMed
12. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol. 1999;154:313–23. Article PubMed PMC
13. Pellegata NS, Quintanilla-Martinez L, Keller G, Liyanarachchi S, Hofler H, Atkinson MJ, et al. Human pheochromocytomas show reduced p27Kip1 expression that is not associated with somatic gene mutations and rarely with deletions. Virchows Arch. 2007;451:37–46. Article PubMed
14. Grabowski P, Schrader J, Wagner J, Horsch D, Arnold R, Arnold CN, et al. Loss of nuclear p27 expression and its prognostic role in relation to cyclin E and p53 mutation in gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res. 2008;14:7378–84. Article PubMed
15. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Hofler H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A. 2006;103:15558–63. Article PubMed PMC
16. Franklin DS, Godfrey VL, O'Brien DA, Deng C, Xiong Y. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol. 2000;20:6147–58. Article PubMed PMC
17. Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, et al. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev. 1998;12:2899–911. Article PubMed PMC
18. Rahman A, Maitra A, Ashfaq R, Yeo CJ, Cameron JL, Hansel DE. Loss of p27 nuclear expression in a prognostically favorable subset of well-differentiated pancreatic endocrine neoplasms. Am J Clin Pathol. 2003;120:685–90. Article PubMed
19. Cavallari I, D'Agostino DM, Ferro T, Rosato A, Barzon L, Pasquali C, et al. In situ analysis of human menin in normal and neoplastic pancreatic tissues: evidence for differential expression in exocrine and endocrine cells. J Clin Endocrinol Metab. 2003;88:3893–901. Article PubMed
20. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer-Verlag; 2009. p. 181–9.
21. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. Lyon: IARC Press; 2010. p. 13–4.
22. Corbo V, Dalai I, Scardoni M, Barbi S, Beghelli S, Bersani S, et al. MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Cancer. 2010;17:771–83. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Menin in Cancer
Ariana D. Majer, Xianxin Hua, Bryson W. Katona
Genes.2024; 15(9): 1231. CrossRef
Current Status of Immunotherapy in Management of Small Bowel Neuroendocrine Tumors
Brittany C. Fields, Reed I. Ayabe, Y. David Seo, Jessica E. Maxwell, Daniel M. Halperin
Current Oncology Reports.2024; 26(11): 1530. CrossRef
Status of Surveillance and Nonsurgical Therapy for Small Nonfunctioning Pancreatic Neuroendocrine Tumors
Dirk-Jan van Beek, Anna Vera D. Verschuur, Lodewijk A.A. Brosens, Gerlof D. Valk, Carolina R.C. Pieterman, Menno R. Vriens
Surgical Oncology Clinics of North America.2023; 32(2): 343. CrossRef
The link between menin and pleiotrophin in the tumor biology of pancreatic neuroendocrine neoplasms
Liping He, Steeve Boulant, Megan Stanifer, Cuncai Guo, Anna Nießen, Mingyi Chen, Klaus Felix, Frank Bergmann, Oliver Strobel, Simon Schimmack
Cancer Science.2022; 113(5): 1575. CrossRef
Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
Meng Dai, Christina S Mullins, Lili Lu, Guido Alsfasser, Michael Linnebacher
World Journal of Gastrointestinal Surgery.2022; 14(5): 383. CrossRef
A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy
Jasminka Hasic Telalovic, Serena Pillozzi, Rachele Fabbri, Alice Laffi, Daniele Lavacchi, Virginia Rossi, Lorenzo Dreoni, Francesca Spada, Nicola Fazio, Amedeo Amedei, Ernesto Iadanza, Lorenzo Antonuzzo
Diagnostics.2021; 11(5): 804. CrossRef
The Role of Conventionally Fractionated Radiotherapy and Stereotactic Radiotherapy in the Treatment of Carcinoid Tumors and Large-Cell Neuroendocrine Cancer of the Lung
Mateusz Bilski, Paulina Mertowska, Sebastian Mertowski, Marcin Sawicki, Anna Hymos, Paulina Niedźwiedzka-Rystwej, Ewelina Grywalska
Cancers.2021; 14(1): 177. CrossRef
The molecular biology of pancreatic neuroendocrine neoplasms: Challenges and translational opportunities
Kate Young, Naureen Starling, Anguraj Sadanandam
Seminars in Cancer Biology.2020; 61: 132. CrossRef
Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine Tumors
Yuki Yamauchi, Yuzo Kodama, Masahiro Shiokawa, Nobuyuki Kakiuchi, Saiko Marui, Takeshi Kuwada, Yuko Sogabe, Teruko Tomono, Atsushi Mima, Toshihiro Morita, Tomoaki Matsumori, Tatsuki Ueda, Motoyuki Tsuda, Yoshihiro Nishikawa, Katsutoshi Kuriyama, Yojiro Sa
Cancer Research.2020; 80(17): 3620. CrossRef
Signaling networks and the feasibility of computational analysis in gastroenteropancreatic neuroendocrine tumors
Pengchen Chen, Qingshui Wang, Jianwei Xie, Hang Fai Kwok
Seminars in Cancer Biology.2019; 58: 80. CrossRef
Reduced expression of the RNA‐binding protein HuD in pancreatic neuroendocrine tumors correlates with low p27Kip1 levels and poor prognosis
Chongtae Kim, Da Eun Jeong, Sungeun Heo, Eunbyul Ji, Jun Gi Rho, Myeongwoo Jung, Sojin Ahn, Ye‐Jin Kim, Yong‐Sung Kim, Suk Woo Nam, Rohit N Kulkarni, Kyoung Bun Lee, Eun Kyung Lee, Wook Kim
The Journal of Pathology.2018; 246(2): 231. CrossRef
Current Standards and Recent Advances in Biomarkers of Major Endocrine Tumors
Yanhong Luo, Hua Zhu, Tao Tan, Jianfeng He
Frontiers in Pharmacology.2018;[Epub] CrossRef
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets
E T Aristizabal Prada, C J Auernhammer
Endocrine Connections.2018; 7(1): R1. CrossRef
Deletion ofMen1andsomatostatininduces hypergastrinemia and gastric carcinoids
Sinju Sundaresan, Anthony J Kang, Michael M Hayes, Eun-Young K Choi, Juanita L Merchant
Gut.2017; 66(6): 1012. CrossRef
Cell Cycle Protein Expression in Neuroendocrine Tumors
Yan Shi, Zhi Rong Qian, Sui Zhang, Wanwan Li, Yohei Masugi, Tingting Li, Jennifer A. Chan, Juhong Yang, Annacarolina Da Silva, Mancang Gu, Li Liu, Tsuyoshi Hamada, Keisuke Kosumi, Trevor Dutton, Lauren K. Brais, Reiko Nishihara, Charles S. Fuchs, Shuji Og
Pancreas.2017; 46(10): 1347. CrossRef
DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications
Iris H. Liu, James M. Ford, Pamela L. Kunz
Cancer Treatment Reviews.2016; 44: 1. CrossRef
Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases
Michelle Kang Kim, Fei Ye, Daguang Wang, Miao Cui, Stephen C. Ward, Richard R.P. Warner, Sasan Roayaie, Michail Shafir, Myron Schwartz, David Zhang, Steven Itzkowitz
Pancreas.2016; 45(4): 528. CrossRef
Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets
Ellinor Andersson, Yvonne Arvidsson, Christina Swärd, Tobias Hofving, Bo Wängberg, Erik Kristiansson, Ola Nilsson
Modern Pathology.2016; 29(6): 616. CrossRef
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
Robert Roskoski
Pharmacological Research.2016; 107: 249. CrossRef
Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts
Joo Young Kim, Seung-Mo Hong
Archives of Pathology & Laboratory Medicine.2016; 140(5): 437. CrossRef
Somatic Mutations and Genetic Heterogeneity at the CDKN1B Locus in Small Intestinal Neuroendocrine Tumors
Joakim Crona, Tobias Gustavsson, Olov Norlén, Katarina Edfeldt, Tobias Åkerström, Gunnar Westin, Per Hellman, Peyman Björklund, Peter Stålberg
Annals of Surgical Oncology.2015; 22(S3): 1428. CrossRef
Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status
Mark Kidd, Ignat Drozdov, Irvin Modlin
Endocrine-Related Cancer.2015; 22(4): 561. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

p27 Loss Is Associated with Poor Prognosis in Gastroenteropancreatic Neuroendocrine Tumors

Cancer Res Treat. 2014;46(4):383-392. Published online July 17, 2014

DOI: https://doi.org/10.4143/crt.2013.102

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusion
NOTES
REFERENCES

p27 Loss Is Associated with Poor Prognosis in Gastroenteropancreatic Neuroendocrine Tumors

Fig. 1. Immunohistochemical expression of menin, p27, and p18 in gastroenteropancreatic neuroendocrine tumors. (A, D, G) menin. (B, E, H) p27. (C, F, I) p18. Upper, gastric neuroendocrine carcinoma with 90% of Ki-67; middle, gastric neuroendocrine tumor with 1% of Ki-67, lower, rectal neuroendocrine tumor with 3% of Ki-67.

Fig. 2. Kaplan-Meier analysis of overall survival in gastroenteropancreatic neuroendocrine tumors. Survival curves according to p27 expression (A), menin expression (B), 4 phenotype groups by combination of menin and p27 expression (C), and dichotomized groups of menin+/p27+ and menin– or p27– (D).

Fig. 1.

Fig. 2.

p27 Loss Is Associated with Poor Prognosis in Gastroenteropancreatic Neuroendocrine Tumors

Characteristic	No. (%) (n=327)
Gender
Female	145 (44)
Male	182 (56)
Clinical history
None	289 (88)
Family history	7 (2)
Symptomatic	26 (8)
Endocrine disorders	5 (2)
Primary site
Stomach	49 (15)
Duodenum	29 (9)
Pancreas	49 (15)
Hepatobiliary	12 (4)
Appendix	33 (10)
Proximal colon	5 (2)
Distal colon	150 (46)
Part
Foregut	139 (43)
Midgut	38 (12)
Hindgut	150 (46)
AJCC stage
I	251 (77)
II	27 (8)
III	23 (7)
IV	25 (8)
Unknown	1 (1)
Comorbidity
None	253 (77)
Malignancy	55 (17)
Benign neoplasm	19 (6)
Adjuvant treatment
No	276 (84)
Yes	51 (16)
Recurrence
Absent	282 (86)
Present	45 (14)
Status
Alive	220 (67)
Deceased	42 (13)
Unknown	65 (20)

Characteristic	Menin		p-value	p27		p-value
Characteristic	Negative	Positive	p-value	Negative	Positive	p-value
Total	100 (34)	194 (66)		61 (21)	229 (79)
Mean age (yr)	55	53		54	53
Gender			0.335			0.742
Female	41 (31)	91 (69)		26 (20)	103 (80)
Male	59 (36)	103 (64)		35 (22)	126 (78)
Part			0.023			<0.001
Foregut	52 (42)	72 (58)		37 (30)	86 (70)
Midgut	13 (37)	22 (63)		11 (33)	22 (67)
Hindgut	35 (26)	100(74)		13 (10)	121 (90)
Location			0.011			0.726
Gastrointestinal tract	76 (31)	170 (69)		50 (21)	192 (79)
Pancreas	24 (50)	24 (50)		11 (23)	37 (77)
WHO 2010 classification			0.629			0.001
NET G1	50 (31)	110 (69)		28 (18)	129 (82)
NET G2	26 (35)	48 (65)		9 (12)	64 (88)
NEC	14 (42)	19 (58)		13 (39)	20 (61)
MANEC	10 (37)	17 (63)		11 (41)	16 (59)
AJCC stage			0.002			0.002
I	63 (28)	160 (72)		37 (17)	182 (83)
II	15 (60)	10 (40)		12 (48)	13 (52)
III	8 (38)	13 (62)		4 (19)	17 (81)
IV	13 (54)	11 (46)		7 (29)	17(71)
Lymph node metastasis			0.065			0.499
Absent	74 (31)	163 (69)		47 (20)	186 (80)
Present	22 (45)	27 (55)		12 (24)	37 (76)

Characteristic	Menin+/p27+	Menin-/p27-	Menin-/p27+	Menin+/p27-	p-value
Total	166 (57)	37 (13)	63 (22)	24 (8)
Mean age (yr)	53	54	55	54
Gender					0.251
Female	74 (57)	12 (9)	29 (22)	14 (11)
Male	92 (57)	25 (16)	34 (21)	10 (6)
Part					0.001
Foregut	57 (46)	23 (19)	29 (24)	14 (11)
Midgut	15 (45)	6 (18)	7 (21)	5 (15)
Hindgut	94 (70)	8 (6)	27 (20)	5 (4)
Gastrointestinal tract vs. pancreas					0.095
Gastrointestinal tract	145 (60)	29 (12)	47 (19)	21 (9)
Pancreas	21 (44)	8 (17)	16 (33)	3 (6)
WHO 2010 classification					0.021
NET G1	96 (61)	17 (11)	33 (21)	11 (7)
NET G2	44 (60)	6 (8)	20 (27)	3 (4)
NEC	13 (39)	7 (21)	7 (21)	6 (18)
MANEC	13 (48)	7 (26)	3 (11)	4 (15)
AJCC stage					0.002
I	141 (64)	22 (10)	41 (19)	15 (7)
II	6 (24)	8 (32)	7 (28)	4 (16)
III	11 (52)	2 (10)	6 (29)	2 (10)
IV	8 (33)	4 (17)	9 (38)	3 (13)
Lymph node metastasis					0.002
Absent	143 (61)	31 (13)	43 (18)	16 (7)
Present	19 (39)	4 (8)	18 (37)	8 (16)

	p27		p-value	Menin		p-value
	Negative	Positive	p-value	Negative	Positive	p-value
Ki-67 grade			0.006			0.055
G1	40 (21)	149 (79)		74 (39)	117 (61)
G2	9 (13)	58 (87)		18 (26)	50 (74)
G3	11 (44)	14 (56)		5 (20)	20 (80)
p18			0.202			0.185
Negative	38 (23)	124 (77)		61 (38)	101 (62)
Positive	22 (17)	105 (83)		39 (30)	90 (70)

Variable	No.	p-value	Hazard ratio	95% CI
Ki-67 grade		0.015		1.2-6.2
G2 or G3	71		2.7
G1	144
Lymph node metastasis		< 0.001		3.2-15.8
Present	38		7.2
Absent	177
p27		< 0.001		3.3-14.0
Negative	37		6.8
Positive	178
Menin		0.091		0.9-4.4
Negative	107		2.0
Positive	108

Table 1. Profile of patients with gastroenteropancreatic neuroendocrine tumors

AJCC, American Joint Committee on Cancer.

Table 2. Clinicopathologic correlations of p27 and menin expressions in gastroenteropancreatic neuroendocrine tumors

Table 3. Clinicopathologic correlations of combined menin and p27 protein expressions in gastroenteropancreatic neuroendocrine tumors

Table 4. Correlation of menin and p27 expression with expression of other proteins in gastroenteropancreatic neuroendocrine tumors